A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial

被引:265
作者
Ross, AM
Coyne, KS
Reiner, JS
Greenhouse, SW
Fink, C
Frey, A
Moreyra, E
Traboulsi, M
Racine, N
Riba, AL
Thompson, MA
Rohrbeck, S
Lundergan, CF
机构
[1] George Washington Univ, Cardiovasc Res Inst, Washington, DC 20037 USA
[2] George Washington Univ, Ctr Biostat, Washington, DC USA
[3] Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada
[4] Notre Dame Hosp, Montreal, PQ, Canada
[5] Oakwood Hosp, Dearborn, MI USA
[6] Rochester Gen Hosp, Rochester, NY 14621 USA
[7] High Point Reg Hosp, High Point, NC USA
关键词
D O I
10.1016/S0735-1097(99)00444-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The study evaluated the efficacy and safety of a short-acting reduced-dose fibrinolytic regimen to promote early infarct-related artery (IRA) patency during the inherent delay experienced by infarct patients referred for angioplasty as the principal recanalization modality. BACKGROUNDS Previous approaches using long-acting, full-dose thrombolytic infusions rarely showed benefit, but they did increase adverse event rates. METHODS Following aspirin and heparin, 606 patients were randomized to a 50-mg bolus of recombinant tissue-type plasminogen activator (rt-PA) (alpha half-life 4.5 min) or to placebo followed by immediate angiography with angioplasty if needed. The end points included patency rates on catheterization laboratory (cath lab) arrival, technical results when PTCA (percutaneous transluminal coronary angioplasty) was performed, complication rates, and left ventricular (LV) function by treatment assignment and time to restored patency following angioplasty. RESULTS Patency on cath lab arrival was 61% with rt-PA (28% Thrombolysis in Myocardial Infarction trial [TIMI]-2, 33% TIMI-3), and 34% with placebo (19% TIMI-2, 15% TIMI-3) (p = 0.001). Rescue and primary PTCA restored TIMI-3 in closed arteries equally (77%, 79%). No differences were observed in stroke or major bleeding. Left ventricular function was similar in both treatment groups, but convalescent ejection fraction (EF) was highest with a patent IRA (TIMI-3) on cath lab arrival (62.4%) or when produced by angioplasty within an hour of bolus (62.5%). However, in 88% of angioplasties, the delay exceeded 1 h: convalescent EF 57.3%. CONCLUSIONS Tailored thrombolytic regimens compatible with subsequent interventions lead to more frequent early recanalization (before cath arrival), which facilitates greater LV function preservation with no augmentation of adverse events. (C) 1999 by the American College of Cardiology.
引用
收藏
页码:1954 / 1962
页数:9
相关论文
共 37 条
[1]   FATE OF PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION WITH PATENCY OF THE INFARCT-RELATED VESSEL ACHIEVED WITH SUCCESSFUL THROMBOLYSIS VERSUS RESCUE ANGIOPLASTY [J].
ABBOTTSMITH, CW ;
TOPOL, EJ ;
GEORGE, BS ;
STACK, RS ;
KEREIAKES, DJ ;
CANDELA, RJ ;
ANDERSON, LC ;
HARRELSONWOODLIEF, SL ;
CALIFF, RM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 16 (04) :770-778
[2]  
[Anonymous], 1989, NEW ENGL J MED, V320, P618
[3]   Abciximab facilitates the rate and extent of thrombolysis - Results of the thrombolysis in myocardial infarction (TIMI) 14 trial [J].
Antman, EM ;
Giugliano, RP ;
Gibson, CM ;
McCabe, CH ;
Coussement, P ;
Kleiman, NS ;
Vahanian, A ;
Adgey, AAJ ;
Menown, I ;
Rupprecht, HJ ;
Van der Wieken, R ;
Ducas, J ;
Scherer, J ;
Anderson, K ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 1999, 99 (21) :2720-2732
[4]  
Betriu A, 1997, NEW ENGL J MED, V336, P1621
[5]  
Bolson E. L., 1980, Computers in Cardiology, P245
[6]   EVALUATION OF COMBINATION THROMBOLYTIC THERAPY AND TIMING OF CARDIAC-CATHETERIZATION IN ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THROMBOLYSIS AND ANGIOPLASTY IN MYOCARDIAL-INFARCTION PHASE-5 RANDOMIZED TRIAL [J].
CALIFF, RM ;
TOPOL, EJ ;
STACK, RS ;
ELLIS, SG ;
GEORGE, BS ;
KEREIAKES, DJ ;
SAMAHA, JK ;
WORLEY, SJ ;
ANDERSON, JL ;
HARRELSONWOODLIEF, L ;
WALL, TC ;
PHILLIPS, HR ;
ABBOTTSMITH, CW ;
CANDELA, RJ ;
FLANAGAN, WH ;
SASAHARA, AA ;
MANTELL, SJ ;
LEE, KL .
CIRCULATION, 1991, 83 (05) :1543-1556
[7]   THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].
CHESEBRO, JH ;
KNATTERUD, G ;
ROBERTS, R ;
BORER, J ;
COHEN, LS ;
DALEN, J ;
DODGE, HT ;
FRANCIS, CK ;
HILLIS, D ;
LUDBROOK, P ;
MARKIS, JE ;
MUELLER, H ;
PASSAMANI, ER ;
POWERS, ER ;
RAO, AK ;
ROBERTSON, T ;
ROSS, A ;
RYAN, TJ ;
SOBEL, BE ;
WILLERSON, J ;
WILLIAMS, DO ;
ZARET, BL ;
BRAUNWALD, E .
CIRCULATION, 1987, 76 (01) :142-154
[8]   A STANDARD HEPARIN NOMOGRAM FOR THE MANAGEMENT OF HEPARIN-THERAPY [J].
CRUICKSHANK, MK ;
LEVINE, MN ;
HIRSH, J ;
ROBERTS, R ;
SIGUENZA, M .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (02) :333-337
[9]  
DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555
[10]   THE USE OF BIPLANE ANGIOCARDIOGRAPHY FOR THE MEASUREMENT OF LEFT VENTRICULAR VOLUME IN MAN [J].
DODGE, HT ;
SANDLER, H ;
BALLEW, DW ;
LORD, JD .
AMERICAN HEART JOURNAL, 1960, 60 (05) :762-776